Abstract
In this study, we investigated and compared the effects of all six sodium-glucose cotransporter (SGLT) 2 inhibitors commercially available in Japan on diabetes-related diseases and complications in type 2 diabetic mice. Following 4-week repeated administration to diabetic mice, all SGLT2 inhibitors showed significant improvement in diabetes-related diseases and complications, including obesity; abnormal lipid metabolism; steatohepatitis; inflammation; endothelial dysfunction; and nephropathy. While all SGLT2 inhibitors exerted comparable effects in reducing hyperglycemia, improvement of these diabetes-related diseases and complications was more potent with the two long-acting drugs (ipragliflozin and dapagliflozin) than with the four intermediate-acting four drugs (tofogliflozin, canagliflozin, empagliflozin, and luseogliflozin), albeit without statistical significance. These findings demonstrate that SGLT2 inhibitors alleviate various diabetic pathological conditions in type 2 diabetic mice, and suggest that SGLT2 inhibitors, particularly long-acting drugs, might be useful not only for hyperglycemia but also in diabetes-related diseases and complications, including nephropathy in type 2 diabetes.
Citations
Jan 6, 2018·International Journal of Molecular Sciences·Dong WangMoshe Levi
Mar 7, 2018·Cardiovascular Drugs and Therapy·Yochai BirnbaumYumei Ye
Jul 12, 2019·Arteriosclerosis, Thrombosis, and Vascular Biology·Rebeca OrtegaLaura Piqueras
Jan 22, 2019·Current Medicinal Chemistry·Anastasios TentolourisNikolaos Tentolouris
Feb 9, 2019·Cardiovascular Diabetology·Damilola D AdingupuAnn-Cathrine Jönsson-Rylander
Apr 20, 2019·Diabetologia·Hiddo J L HeerspinkGert Mayer
Jan 25, 2020·Naunyn-Schmiedeberg's Archives of Pharmacology·Mitsuhiro KondoYuichi Tomura
Jun 15, 2020·Cardiovascular Diabetology·Atsushi TanakaUNKNOWN PROCEED trial investigators
Jul 28, 2020·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Afnan S AlshnbariIskandar Idris
Jul 13, 2019·International Journal of Molecular Sciences·Keiichiro MatobaRimei Nishimura
Nov 30, 2019·Physiological Reports·Atsuo Tahara, Toshiyuki Takasu
Apr 18, 2019·Clinical Drug Investigation·Yoshitaka AraseTatehiro Kagawa
Sep 21, 2018·Clinical Science·Giulia Ferrannini, Lars Rydén
Nov 24, 2020·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Yupeng JiangLijian Tao
May 16, 2020·Drug Discovery Today·Frederikke E SembachLisbeth N Fink
Oct 28, 2020·Biology·Stephanie A EidEva L Feldman
Jan 15, 2021·International Journal of Molecular Sciences·María Aguilar-BallesterHerminia González-Navarro
Apr 3, 2021·European Journal of Pharmacology·Atsuo Tahara
Jun 17, 2021·Nature Reviews. Endocrinology·Daniel Ferguson, Brian N Finck
Dec 23, 2019·Cardiology·Diogo Santos-FerreiraRicardo Fontes-Carvalho